What is Bristol Myers Squibb's primary goal in partnering with Anthropic and deploying the Claude AI model?

Bristol Myers Squibb's primary goal is to accelerate the discovery, development, and delivery of new medicines by making Anthropic's Claude AI model available to over 30,000 employees, and by leveraging Claude Code—a coding tool—to support research, drug development, manufacturing, and commercial and medical affairs.

According to Bristol Myers Squibb's chief digital and technology officer, what key challenge does this AI collaboration aim to address?

According to Greg Meyers, chief digital and technology officer at Bristol Myers Squibb, the collaboration aims to unlock 'the untapped value still trapped behind decades of data silos'—a challenge that goes beyond basic enterprise AI chatbots and targets deeper, integrated use of institutional knowledge and historical data.

Bristol Myers to deploy Anthropic's Claude AI model to speed up drug discovery

May 20, 2026

Bristol Myers Squibb partners with Anthropic to deploy Claude AI across 30,000 employees to accelerate drug discovery and manufacturing. The initiative aims to leverage agentic AI to potentially boost clinical development productivity by up to 45% within five years.

reuters

2026-04-30

Bristol Myers beats quarterly profit estimates on blood thinner, cancer drug sales

2026-05-15

BMS Is Latest Big Pharma Firm to Partner with China’s Hengrui

2026-05-20

Bristol Myers to deploy Anthropic's Claude AI model to speed up drug discovery

2026-07-30

Bristol Myers raises 2026 forecast as Eliquis, newer medicines power results

Bristol Myers to deploy Anthropic's Claude AI model to speed up drug discovery

FAQ